LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article: Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition.

Ni, Kevin / Hawkins, R Matthew / Smyth, Heather L / Seggelke, Stacey A / Gibbs, Joanna / Lindsay, Mark C / Kaizer, Laura K / Low Wang, Cecilia C

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2024 Volume 30, Issue 4, Page(s) 367–371

Abstract: Objective: There is a relative lack of consensus regarding the optimal management of hyperglycemia in patients receiving continuous enteral nutrition (EN), with or without a diagnosis of diabetes.: Methods: This retrospective study examined 475 ... ...

Abstract	Objective: There is a relative lack of consensus regarding the optimal management of hyperglycemia in patients receiving continuous enteral nutrition (EN), with or without a diagnosis of diabetes. Methods: This retrospective study examined 475 patients (303 with known diabetes) hospitalized in critical care setting units in 2019 in a single center who received continuous EN. Rates of hypoglycemia, hyperglycemia, and glucose levels within the target range (70-180 mg/dL) were compared between patients with and without diabetes, and among patients treated with intermediate-acting (IA) biphasic neutral protamine Hagedorn 70/30, long-acting (LA) insulin, or rapid-acting insulin only. Results: Among those with type 2 diabetes mellitus, IA and LA insulin regimens were associated with a significantly higher proportion of patient-days in the target glucose range and fewer hyperglycemic days. Level 1 (<70 mg/dL) and level 2 (<54 mg/dL) hypoglycemia occurred rarely, and there were no significant differences in level 2 hypoglycemia frequency across the different insulin regimens. Conclusion: Administration of IA and LA insulin can be safe and effective for those receiving insulin doses for EN-related hyperglycemia.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Retrospective Studies ; Enteral Nutrition ; Critical Illness/therapy ; Blood Glucose ; Insulin/adverse effects ; Hypoglycemia/chemically induced ; Hypoglycemia/epidemiology ; Hypoglycemia/drug therapy ; Insulin, Long-Acting/therapeutic use ; Hyperglycemia/drug therapy ; Hyperglycemia/prevention & control ; Hyperglycemia/chemically induced ; Glucose/therapeutic use ; Insulin, Isophane/adverse effects
Chemical Substances	Hypoglycemic Agents ; Blood Glucose ; Insulin ; Insulin, Long-Acting ; Glucose (IY9XDZ35W2) ; Insulin, Isophane (53027-39-7)
Language	English
Publishing date	2024-02-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	1473503-9
ISSN	1530-891X
ISSN	1530-891X
DOI	10.1016/j.eprac.2024.01.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Hitting the target for inpatient glycemic management.

Seggelke, Stacey A

The Nurse practitioner

2011 Volume 36, Issue 5, Page(s) 24–31; quiz 31–2

Abstract: Hyperglycemia in the hospital setting can lead to increased morbidity and mortality. Many factors can influence glucose levels including critical illness, supplemental feeding, and glucocorticoid administration. An understanding of glycemic treatment ... ...

Abstract	Hyperglycemia in the hospital setting can lead to increased morbidity and mortality. Many factors can influence glucose levels including critical illness, supplemental feeding, and glucocorticoid administration. An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes.
MeSH term(s)	Critical Illness/nursing ; Critical Illness/therapy ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/nursing ; Education, Nursing, Continuing ; Humans ; Hyperglycemia/diagnosis ; Hyperglycemia/drug therapy ; Hyperglycemia/nursing ; Hypoglycemic Agents/therapeutic use ; Nurse Practitioners ; Prediabetic State/diagnosis ; Prediabetic State/drug therapy ; Prediabetic State/nursing
Chemical Substances	Hypoglycemic Agents
Language	English
Publishing date	2011-05
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	604085-8
ISSN	1538-8662 ; 0361-1817
ISSN (online)	1538-8662
ISSN	0361-1817
DOI	10.1097/01.NPR.0000396471.76436.ef
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2398: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Insulin Resistance in a Hospitalized COVID-19 Patient: A Case Review.

Seggelke, Stacey A / Ingram, Claire C / Crawley, Svitlana / Low Wang, Cecilia C

Clinical diabetes : a publication of the American Diabetes Association

2021 Volume 39, Issue 2, Page(s) 228–232

Language	English
Publishing date	2021-04-16
Publishing country	United States
Document type	Case Reports
ZDB-ID	1025953-3
ISSN	0891-8929
ISSN	0891-8929
DOI	10.2337/cd20-0036
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2591: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes.

Seggelke, Stacey A / Gibbs, Joanna / Draznin, Boris

Journal of hospital medicine

2011 Volume 6, Issue 3, Page(s) 175–176

MeSH term(s)	Cystic Fibrosis/complications ; Cystic Fibrosis/drug therapy ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/etiology ; Hospitalization ; Humans ; Insulin, Isophane/therapeutic use ; Methylprednisolone/antagonists & inhibitors ; Methylprednisolone/therapeutic use ; Pilot Projects
Chemical Substances	Insulin, Isophane (53027-39-7) ; Methylprednisolone (X4W7ZR7023)
Language	English
Publishing date	2011-03
Publishing country	United States
Document type	Comparative Study ; Letter
ZDB-ID	2233783-0
ISSN	1553-5606 ; 1553-5592
ISSN (online)	1553-5606
ISSN	1553-5592
DOI	10.1002/jhm.874
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6276: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 542: Show issues

Order via subito

Details ▾

Article ; Online: Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.

Seggelke, Stacey A / Lindsay, Mark C / Hazlett, Ingrid / Sanagorski, Rebecca / Eckel, Robert H / Low Wang, Cecilia C

Current diabetes reports

2017 Volume 17, Issue 8, Page(s) 64

Abstract: Purpose of review: Patients with diabetes and/or stress hyperglycemia requires good glycemic control in the hospital setting, often requiring the use of glucose-lowering therapy. Standard-of-care dictates that non-insulin therapy be discontinued, with ... ...

Abstract	Purpose of review: Patients with diabetes and/or stress hyperglycemia requires good glycemic control in the hospital setting, often requiring the use of glucose-lowering therapy. Standard-of-care dictates that non-insulin therapy be discontinued, with insulin therapy initiated using a basal-bolus approach. However, insulin is associated with a high risk for hypoglycemia and medical errors. Alternatives to insulin are needed in the inpatient setting, but the cardiovascular (CV) safety of non-insulin therapy is a concern. Recent findings: Most studies of antidiabetic drugs have been performed in the outpatient setting, and except for insulin therapy, trials in the inpatient setting have been insufficient to establish CV safety. Randomized controlled trials support the safety of insulin with more moderate glycemic control in the hospital, when hypoglycemia is minimized. Two recent multicenter randomized controlled clinical trials support the safety of sitagliptin, a dipeptidylpeptidase-4 inhibitor (DPP4i), in hospitalized patients, although the sample sizes were likely too small to detect CV events. Small trials suggest a possible CV benefit of glucagon-like peptide-1 receptor agonist therapy. A paucity of evidence and presence of side effects and cautions with insulin secretagogues, sodium glucose-co-transporter-2 inhibitors, and metformin preclude their routine use in the hospital setting. Available evidence is inadequate to evaluate the CV safety of most antidiabetic drug classes in the hospital setting. However, preliminary data from randomized clinical trials suggest the potential safety of the DPP4i sitagliptin.
MeSH term(s)	Cardiovascular System/drug effects ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Hospitals ; Humans ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Risk Factors
Chemical Substances	Hypoglycemic Agents
Language	English
Publishing date	2017
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2065167-3
ISSN	1539-0829 ; 1534-4827
ISSN (online)	1539-0829
ISSN	1534-4827
DOI	10.1007/s11892-017-0884-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5628: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Transitional care clinic for uninsured and medicaid-covered patients with diabetes mellitus discharged from the hospital: a pilot quality improvement study.

Seggelke, Stacey A / Hawkins, R Mathew / Gibbs, Joanna / Rasouli, Neda / Wang, Cecilia / Draznin, Boris

Hospital practice (1995)

2014 Volume 42, Issue 1, Page(s) 46–51

Abstract: Transitioning from the inpatient to outpatient setting is often a problematic aspect of diabetes mellitus (DM) care. Different factors during hospitalization may adversely affect glycemic control in patients, who are frequently discharged on regimens ... ...

Abstract	Transitioning from the inpatient to outpatient setting is often a problematic aspect of diabetes mellitus (DM) care. Different factors during hospitalization may adversely affect glycemic control in patients, who are frequently discharged on regimens that differ markedly from prehospitalization outpatient regimens. Moreover, the discharge recommendations may not have been tested adequately during a relatively short hospital length of stay and pose a significant threat to patient safety upon discharge. Our pilot study evaluated the effect on hospital utilization of the transitional care clinic (TCC), where patients with DM are seen within 2 to 5 days of hospital discharge. One hundred patients with DM, who were either medically indigent (no insurance or Medicaid and no primary care providers) or covered by Medicaid, and who did not have a primary care provider, were randomized into either a control or an intervention group upon discharge from the hospital. Subjects from the intervention group (n = 50) were seen in the TCC. All subjects were contacted 90 days after discharge to collect information about emergency department visits and readmissions. Thirteen subjects from the control group and 13 from the intervention group visited the emergency department within 90 days of discharge. Fourteen control subjects (28%) and 10 intervention patients (20%) were rehospitalized for various medical conditions during the follow-up period (P = not significant). Among patients originally admitted for DM-related issues, 6 of 14 in the control group (42.9%) and 2 out of 16 in the intervention group (12.5%) were readmitted during follow-up (P < 0.05). We conclude that the TCC may be effective for the prevention of rehospitalizations in indigent patients admitted for DM-related problems and who did not have primary care providers. The benefit of the TCC was not seen when patients with DM were admitted for other medical problems. Larger randomized controlled trials are needed to confirm this preliminary finding.
MeSH term(s)	Colorado ; Continuity of Patient Care/statistics & numerical data ; Diabetes Mellitus/therapy ; Female ; Humans ; Male ; Medicaid ; Medically Uninsured ; Middle Aged ; Patient Discharge/statistics & numerical data ; Patient Readmission/statistics & numerical data ; Pilot Projects ; Quality Improvement ; United States
Language	English
Publishing date	2014-02
Publishing country	England
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2570453-9
ISSN	2377-1003 ; 2154-8331 ; 8750-2836
ISSN (online)	2377-1003
ISSN	2154-8331 ; 8750-2836
DOI	10.3810/hp.2014.02.1091
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 890: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.

Seggelke, Stacey A / Hawkins, R Matthew / Gibbs, Joanna / Rasouli, Neda / Wang, Cecilia C Low / Draznin, Boris

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2013 Volume 20, Issue 6, Page(s) 536–539

Abstract: Objective: To evaluate the effects of two different glargine insulin delivery methods (pen device vs. vial/syringe) on glycemic control and patient preferences in a randomized, open-label, crossover, comparative effectiveness study.: Methods: Thirty- ... ...

Abstract	Objective: To evaluate the effects of two different glargine insulin delivery methods (pen device vs. vial/syringe) on glycemic control and patient preferences in a randomized, open-label, crossover, comparative effectiveness study. Methods: Thirty-one patients discharged from the hospital were recruited for this study. In the hospital, all patients were treated with a basal-bolus insulin regimen. Upon discharge, 21 patients received glargine by pen device for 3 months and were then switched to vial/syringe for the next 3 months (group 1). Group 2 consisted of 10 patients discharged on vial/syringe and converted to pen device after 3 months. Hemoglobin A1c (HbA1c) was measured at enrollment and at 3 and 6 months. A questionnaire assessing patient preference was administered at 3 and 6 months. Results: Groups 1 and 2 had similar baseline HbA1c (10.7 ± 2.2% and 11.2 ± 2.5%, respectively) and similar reduction in HbA1c at 3 months (7.8 ± 1.7% and 7.3 ± 1.4%, respectively; P<.001 vs. baseline). However, after crossover, the changes in HbA1c from 3 to 6 months were significantly different between groups. HbA1c increased to 8.5 ± 2.0% at 6 months in group 1 after switching to the vial/syringe but remained unchanged (7.1 ± 1.6%) in group 2 after switching to a pen device (P<.01, group 1 vs. group 2). Patient questionnaires after each phase of the trial revealed that patients found the pen device more convenient and were more likely to recommend this insulin delivery method to someone else. Conclusion: Patients switching to a glargine pen device achieved lower HbA1c at the 6-month follow-up. Patients in both groups overwhelmingly preferred glargine pens over vials/syringes.
MeSH term(s)	Adult ; Aged ; Blood Glucose/analysis ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Glycated Hemoglobin A/analysis ; Humans ; Hypoglycemic Agents/administration & dosage ; Insulin Glargine/administration & dosage ; Male ; Middle Aged ; Patient Preference
Chemical Substances	Blood Glucose ; Glycated Hemoglobin A ; Hypoglycemic Agents ; hemoglobin A1c protein, human ; Insulin Glargine (2ZM8CX04RZ)
Language	English
Publishing date	2013-09-26
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1473503-9
ISSN	1530-891X
ISSN	1530-891X
DOI	10.4158/EP13404.OR
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.

Hsia, Elisa / Seggelke, Stacey A / Gibbs, Joanna / Rasouli, Neda / Draznin, Boris

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

2011 Volume 26, Issue 6, Page(s) 714–717

Abstract: Despite significant advances in inpatient diabetes management, it is still a challenge to choose the safest and most efficacious subcutaneous insulin regimen for diabetic patients on continuous enteral nutrition (EN) therapy. The authors conducted a ... ...

Abstract	Despite significant advances in inpatient diabetes management, it is still a challenge to choose the safest and most efficacious subcutaneous insulin regimen for diabetic patients on continuous enteral nutrition (EN) therapy. The authors conducted a retrospective analysis of glycemic control in 22 non-critically ill diabetic patients, receiving at least 3 days of continuous EN. Patients received different insulin regimens while on continuous EN, including a basal/bolus glargine/lispro regimen (group 1, n = 8), 70/30 biphasic insulin twice daily (group 2, n = 8), and 70/30 biphasic insulin 3 times a day (group 3, n = 6). The glucose data from 72 hours from the initiation of EN were analyzed (12 point-of-contact glucose measurements per patient). Overall, the degree of control was comparable in all groups, with target range maintained more consistently in group 3 (70/30 insulin administered 3 times daily). In this group, 69% of values were in the target range (140-180 mg/dL) as compared with 24% in glargine/lispro group and 22% in the 70/30 insulin bid group. Eight hypoglycemic episodes occurred among the 3 groups: 5 episodes in group 1 (5.4%), 2 episodes in group 2 (2.1%), and 1 episode in group 3 (1.4%) (P = .05, groups 2 and 3 vs group 1). Administration of 70/30 biphasic insulin 3 times daily is a safe therapeutic regimen in diabetic patients on continuous EN as it maintains glycemia in the target range and might produce fewer episodes of hypoglycemia.
MeSH term(s)	Adult ; Aged ; Biphasic Insulins/administration & dosage ; Biphasic Insulins/analysis ; Blood Glucose ; Diabetes Mellitus/therapy ; Dose-Response Relationship, Drug ; Enteral Nutrition/methods ; Hospitalization ; Humans ; Hypoglycemia/therapy ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/analysis ; Insulin Glargine ; Insulin Lispro/administration & dosage ; Insulin Lispro/analysis ; Insulin, Long-Acting/administration & dosage ; Insulin, Long-Acting/analysis ; Middle Aged ; Retrospective Studies ; Young Adult
Chemical Substances	Biphasic Insulins ; Blood Glucose ; Hypoglycemic Agents ; Insulin Lispro ; Insulin, Long-Acting ; Insulin Glargine (2ZM8CX04RZ)
Language	English
Publishing date	2011-12
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	645074-x
ISSN	1941-2452 ; 0884-5336
ISSN (online)	1941-2452
ISSN	0884-5336
DOI	10.1177/0884533611420727
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2451: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito